Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
University of Florida
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Medtronic Cardiovascular
Dana-Farber Cancer Institute
Galapagos NV
Merck Sharp & Dohme LLC
BeOne Medicines
M.D. Anderson Cancer Center
University of Washington
National Institutes of Health Clinical Center (CC)
Genmab
Genmab
Novartis
Thomas Jefferson University
Actinogen Medical
Big Ten Cancer Research Consortium
Regeneron Pharmaceuticals
Cognito Therapeutics, Inc.
University of Texas at Austin
Hoffmann-La Roche
H. Lee Moffitt Cancer Center and Research Institute
City of Hope Medical Center
Hennepin Healthcare Research Institute
University of Michigan Rogel Cancer Center
National Medical Research Center for Therapy and Preventive Medicine
Rush University Medical Center
Celgene
Fred Hutchinson Cancer Center
Eisai Inc.
City of Hope Medical Center
Incyte Corporation
Swedish Orphan Biovitrum
M.D. Anderson Cancer Center
Washington University School of Medicine
Fondazione Italiana Linfomi - ETS
Sana Biotechnology
City of Hope Medical Center
Brigham and Women's Hospital
Oncology Institute of Southern Switzerland
National Cancer Institute (NCI)
Celgene
University of Washington
Memorial Sloan Kettering Cancer Center
Immunitas Therapeutics
Ohio State University Comprehensive Cancer Center